Intravenous Immunoglobulins in Severe and Refractory Solar Urticaria
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Solar urticaria is a rare but debilitating disease that can severely impact the quality of
life, restricting outdoor activities.Treatment, based on sun protection and anti-histaminic
drugs, is efficacious in 2 patients out of 3. In refractory patients, photodesensitization or
immunosuppressive treatments such as cyclosporin A can be proposed. As in idiopathic
urticaria, intravenous immunoglobulins (IVIG)have been shown, in a retrospective study of 7
patients, to dramatically improve 71% of patients. In an open-label prospective multicenter
study, we aim to demonstrate the efficacy of a single IVIG administration (2g/kg) in 10
patients affected with severe and refractory solar urticaria.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Collaborators:
Ministry of Health, France Saint-Louis Hospital, Paris, France